Market Snapshot
  • U.S.
  • Europe
  • Asia
Ticker Volume Price Price Delta
DJIA 16,408.54 -16.31 -0.10%
S&P 500 1,864.85 2.54 0.14%
NASDAQ 4,095.52 9.29 0.23%
Ticker Volume Price Price Delta
STOXX 50 3,155.81 16.55 0.53%
FTSE 100 6,625.25 41.08 0.62%
DAX 9,409.71 91.89 0.99%
Ticker Volume Price Price Delta
NIKKEI 14,516.27 98.74 0.68%
TOPIX 1,173.37 6.78 0.58%
HANG SENG 22,760.24 64.23 0.28%

MagForce AG Installs NanoActivator(r) at the University Hospital Munster



MagForce AG Installs NanoActivator(r) at the University Hospital Munster

BERLIN, Germany, Nov. 6, 2013 (GLOBE NEWSWIRE) --

MagForce AG (Frankfurt, Xetra: MF6), a
medical technology company that focuses on the field of oncology and is a leader
in the nanotechnology sector, today announced the installation of the second
NanoActivator®. The NanoActivator® was brought into operation as part of the
preparations for the new glioblastoma study at the University Hospital Münster
and is the second after the one at the university hospital Charité in Berlin.

Prof.  Dr.  med.  Walter  Stummer,  Director  of the Clinic for Neurosurgery and
Neurooncology  at the University  Hospital Münster and  head of the new clinical
trial,  said:  "I  am  extremely  happy  to  say  that my center now has its own
NanoActivator®  and we  can commence  recruitment into  this important  study in
neuro-oncology.  We anticipate a significant added  value to the technology once
we  have more  experience in  its use  for therapy  and are eager for generating
additional  data  on  efficacy  from  a  randomized study. We are continually in
contact with the clinical team at MagForce AG for directly communicating current
developments in the progress of the study."

Prof.   Dr.   Hoda   Tawfik,  CMO/COO  of  MagForce  AG:  "Since  the  start  of
considerations  about a  new glioblastoma  study, we  have been in close contact
with  important  medical  opinion  leaders  in  neurooncology.  They contributed
significantly  to the  creation of  the study  design. With  the installation of
another  NanoActivator®, we  are an  important step  closer to  introducing this
therapy  to the medical community.  Our goal is to  take NanoTherm(®) therapy to
the next level and to corroborate previous clinical results."

The   new   glioblastoma   study  aims  to  validate  the  previous  results  of
NanoTherm® therapy  in direct comparison to currently available standard therapy
in  a  larger  patient  pool.  This  will  allow  the company to draw meaningful
conclusions  about the potential of this  new approach to treating patients with
glioblastomas.  The  patients  recruitment  in  this new glioblastoma study will
start  end of 2013. Until then, a total  of three NanoActivators® are planned to
be set up and operational. Additional centers will follow in 2014.

About MagForce AG
MagForce  AG is a leading medical device company in the field of nanomedicine in
oncology,  listed  in  the  entry  standard  (MF6).  The  Company's proprietary,
NanoTherm(®) therapy, enables the targeted treatment of solid tumors through the
intratumoral   generation   of   heat   via   activation   of  superparamagnetic
nanoparticles.  NanoTherm(®), NanoPlan(®), and  NanoActivator® are components of
the therapy and have received EU-wide regulatory approval as medical devices for
the   treatment  of  brain  tumors.  MagForce,  NanoTherm(®),  NanoPlan(®),  and
NanoActivator®  are trademarks  of MagForce  AG in  selected countries. For more
information, please visit www.magforce.com.

Disclaimer
This release may contain forward-looking statements and information which may be
identified by formulations using terms such as "expects", "aims", "anticipates",
"intends",  "plans", "believes",  "seeks", "estimates"  or "will". Such forward-
looking   statements   are   based  on  our  current  expectations  and  certain
assumptions,  which may be subject to a  variety of risks and uncertainties. The
results  actually achieved  by MagForce  AG may  substantially differ from these
forward-looking  statements. MagForce AG  assumes no obligation  to update these
forward-looking  statements or  to correct  them in  case of developments, which
differ from those, anticipated.

Contact:
Anne Hennecke
MC Services AG

T +49 89 210228-18
F +49 89 210228-88
M +49 151 12 555 759
Email: anne.hennecke@mc-services.eu


MagForce_PRess Release_Nov 06, 2013: http://hugin.info/143761/R/1740916/584737.pdf

[HUG#1740916]
Sponsored Links
Advertisement
Advertisements
Sponsored Links
Advertisement